Based on these results, the US Food and Drug Administration approved pembrolizumab for the treatment of patients with recurrent or metastatic G/GEJ adenocarcinoma whose tumors express PD-L1 and whose disease has progressed on or after ≥ 2 prior lines of therapy [20]. Here, CD274 is linked to gastroesophageal junction adenocarcinoma.